{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:59Z","timestamp":1786987019138,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinthera.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T19:14:25Z","timestamp":1706814865000},"page":"267-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Fuxin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.12.010_bib0001","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00003086-200003000-00016","author":"Lane","year":"2000","journal-title":"Clinical orthopaedics and related research"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcdb.2021.05.014","article-title":"Interaction between bone and immune cells: Implications for postmenopausal osteoporosis","volume":"123","author":"Fischer","year":"2022","journal-title":"Seminars in cell & developmental biology"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.beem.2018.09.005","article-title":"Postmenopausal osteoporosis: Assessment and management","volume":"32","author":"Rizzoli","year":"2018","journal-title":"Best practice research clinical endocrinology metabolism"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/gerona\/glt071","article-title":"Age- and menopause-related bone loss compromise cortical and trabecular microstructure","volume":"68","author":"Seeman","year":"2013","journal-title":"The Journals of gerontology. Series A, Biological sciences and medical sciences"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0006","first-page":"105","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes","year":"2020","journal-title":"British medical bulletin"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0007","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"Journal of orthopaedic surgery and research"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0008","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Archives of osteoporosis"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0009","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","article-title":"Osteoporosis in older adults","volume":"104","author":"Johnston","year":"2020","journal-title":"The Medical clinics of North America"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0010","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1177\/1060028020970518","article-title":"Economic burden of osteoporosis-related fractures in the US Medicare population","volume":"55","author":"Williams","year":"2021","journal-title":"The Annals of pharmacotherapy"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporosis international"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0012","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0013","series-title":"StatPearls","author":"Rodriguez","year":"2022"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4062\/biomolther.2022.007","article-title":"Metabolic bone diseases and new drug developments","volume":"30","author":"Natesan","year":"2022","journal-title":"Biomolecules & therapeutics"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"Journal of cellular biochemistry"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0016","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2019.05.024","article-title":"Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide","volume":"166","author":"Bhattacharyya","year":"2019","journal-title":"Biochemical pharmacology"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0019","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00223-013-9755-1","article-title":"Effects of different dosages of parathyroid hormone-related protein 1-34 on the bone metabolism of the ovariectomized rat model of osteoporosis","volume":"93","author":"Xu","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1359\/jbmr.2000.15.8.1517","volume":"15","author":"Stewart","year":"2000","journal-title":"Journal of bone and mineral research"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0021","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 Months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0022","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0023","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","article-title":"Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis","volume":"30","author":"Watts","year":"2019","journal-title":"Osteoporosis international"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0024","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clinic proceedings"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0025","unstructured":"US Food and Drug Administration. Drug Trial Snapshot: TYMLOS: The United States government; 2020."},{"key":"10.1016\/j.clinthera.2023.12.010_bib0026","series-title":"Tymlos (abaloparatide) injection, for subcutaneous use","year":"2017"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0027","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14656566.2019.1583208","article-title":"Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis","volume":"20","author":"Merlotti","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0028","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0029","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0030","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.clinthera.2020.04.012","article-title":"Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture","volume":"42","author":"Saag","year":"2020","journal-title":"Clinical therapeutics"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0031","doi-asserted-by":"crossref","first-page":"e4222","DOI":"10.1210\/clinem\/dgac486","article-title":"Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the Phase 3 ACTIVE-J Study","volume":"107","author":"Matsumoto","year":"2022","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0032","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/GME.0000000000001593","article-title":"Abaloparatide followed by alendronate in women \u226580 years with osteoporosis: post hoc analysis of ACTIVExtend","volume":"27","author":"Greenspan","year":"2020","journal-title":"Menopause (New York, N.Y.)"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0033","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0034","series-title":"Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis","year":"2012"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0036","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0037","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0000000000000616","article-title":"The evolving role of anabolic therapy in the treatment of osteoporosis","volume":"31","author":"Cosman","year":"2019","journal-title":"Current opinion in rheumatology"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0038","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajhp\/zxy022","article-title":"Abaloparatide: A new pharmacological option for osteoporosis","volume":"76","author":"Sleeman","year":"2019","journal-title":"American journal of health-system pharmacy"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0039","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporosis international"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bcp.13455","article-title":"Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism\u2014translating the pharmacology","volume":"84","author":"Tay","year":"2018","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0041","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0042","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause (New York, N.Y.)"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0043","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0044","first-page":"S453","article-title":"BA058, a novel analog of human parathyroid hormone-related protein: early P1NP elevation precedes BMD gains in postmenopausal women with osteoporosis","volume":"23","author":"Hattersley","year":"2012","journal-title":"Osteoporosis international"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0045","first-page":"11","article-title":"Parathyroid hormone-related peptide and its analog, abaloparatide, attenuate lethal myocardial ischemia-reperfusion injury","author":"Wider","year":"2022","journal-title":"Journal of clinical medicine"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0046","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: Analysis from the ACTIVE Phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116610","article-title":"Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis","volume":"167","author":"Seeto","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2023.12.010_bib0048","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regulatory toxicology and pharmacology : RTP."},{"key":"10.1016\/j.clinthera.2023.12.010_bib0049","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/jbmr.4049","article-title":"Osteoporosis Management in the Era of COVID-19","volume":"35","author":"Yu","year":"2020","journal-title":"Journal of bone and mineral research"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:58:40Z","timestamp":1729097920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0149291824000043"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}